EN DE
STOCK COMPARISON

Rani Zim Shopping Centers vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Rani Zim Shopping Centers (RANI) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Rani Zim Shopping Centers as the more attractively valued of the two: Rani Zim Shopping Centers trades at ILS 4.84 versus a fair value of ILS 5.63 (+16%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Rani Zim Shopping Centers
RANI.TA · ILS · Real Estate
+16%
upside to fair value
undervalued
PriceILS 4.84
Fair ValueILS 5.63
Quality34/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Rani Zim Shopping CentersVertex Pharmaceuticals
Valuation
9.0×P/E (TTM)28.8×
0.99×P/S (TTM)10.06×
0.28×P/B6.59×
10.9×EV/EBITDA23.8×
PEG1.72×
0.0%Dividend yield
Profitability
34%Net margin36%
43%Operating margin38%
10%Return on equity24%
3%Return on assets12%
Growth
-30%Revenue growth (YoY)8%
23.2%Avg. growth/yr (3Y)10.6%
32.1%Avg. growth/yr (5Y)14.2%
Balance & size
1.69×Debt / equity0.03×
$278MMarket cap$123B
mixedGrowth qualityhealthy

Rani Zim Shopping Centers leads: 7 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Rani Zim Shopping Centersof which business quality 33 · market factors 51 Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
35
72
Quality GrowthAre margins and returns improving?
29
65
CashflowEarnings quality: real cash, not paper profit
69
79
Fin. StrengthBalance sheet, leverage, solvency risk
10
92
InvestmentDisciplined investing over empire-building
48
58
Low VolatilityCalm price path (market factor)
78
86
MomentumPrice trend over the last 3–12 months (market factor)
41
54
52W MomentumDistance to the 52-week high (market factor)
37
59
Net IssuanceBuybacks instead of dilution
0
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Rani Zim Shopping Centers

Dividend DiscountILS 2.77
MultiplesILS 7.30
Asset-BasedILS 3.81
Economic ProfitILS 4.75

4 of 6 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Rani Zim Shopping Centers
Bear ILS 4.22Fair Value ILS 5.63Bull ILS 5.63
ILS 4.84 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Rani Zim Shopping Centers · Real Estate

Quality score34 · bottom 25%
Fair value upside+16% · above median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-44% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Rani Zim Shopping Centers as the more attractively valued of the two: Rani Zim Shopping Centers trades at ILS 4.84 versus a fair value of ILS 5.63 (+16%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.